Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome

The Lancet Respiratory Medicine

Volumn 5, Issue 6, 2017, Pages 512-523

  Meyer, Nuala J ^a   Calfee, Carolyn S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; GENOMIC DNA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RNA;

ADULT RESPIRATORY DISTRESS SYNDROME; ANG2 GENE; BIOENGINEERING; CLINICAL TRIAL (TOPIC); CRISPR CAS SYSTEM; DNA CLEAVAGE; DRUG RESEARCH; EX VIVO LUNG PERFUSION; GENE; GENE EXPRESSION PROFILING; GENETIC RISK; GENETIC VARIABILITY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMAN; LUNG ENDOTHELIUM; LUNG PERFUSION; METABOLOMICS; MICROBIOME; MICROFLORA; MICROFLUIDICS; MORTALITY; NEXT GENERATION SEQUENCING; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE TRAIT; RESPIRATORY EPITHELIAL DYSFUNCTION; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; TRANSCRIPTOMICS; VENTILATOR; METABOLISM; METHODOLOGY; MICROBIOLOGY; PROCEDURES; RISK FACTOR;

BIOMARKERS; GENE EXPRESSION PROFILING; HUMANS; METABOLOMICS; MICROBIOTA; PRECISION MEDICINE; PROTEOMICS; RESEARCH DESIGN; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS;

EID: 85019686560     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30187-X     Document Type: Review

References (107)

1. Ashbaugh, DG, Bigelow, DB, Petty, TL, Levine, BE, Acute respiratory distress in adults. Lancet 290 (1967), 319–323.
2. Network, ARDS, Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342 (2000), 1301–1308.
3. Dellinger, RP, Levy, MM, Rhodes, A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39 (2013), 165–228.
4. Rhodes, A, Evans, LE, Alhazzani, W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45 (2017), 486–552.
5. Ouellette, DR, Patel, S, Girard, TD, et al. Liberation from mechanical ventilation in critically ill adults: an official American College of Chest Physicians/American Thoracic Society clinical practice guideline: inspiratory pressure augmentation during spontaneous breathing trials, protocols minimizing sedation, and noninvasive ventilation immediately after extubation. Chest 151 (2017), 166–180.
6. Girard, TD, Alhazzani, W, Kress, JP, et al. An official American Thoracic Society/American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Rehabilitation protocols, ventilator liberation protocols, and cuff leak tests. Am J Respir Crit Care Med 195 (2017), 120–133.
7. Bellani, G, Laffey, JG, Pham, T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315 (2016), 788–800.
8. Ranieri, VM, Rubenfeld, GD, Thompson, BT, et al., for the ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307 (2012), 2526–2533.
9. Papazian, L, Forel, JM, Gacouin, A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 363 (2010), 1107–1116.
10. Truwit, JD, Bernard, GR, Steingrub, J, et al., for the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 370 (2014), 2191–2200.
11. McAuley, DF, Laffey, JG, O'Kane, CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371 (2014), 1695–1703.
12. Smith, FG, Perkins, GD, Gates, S, et al., for the BALTI-2 study investigators. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 379 (2012), 229–235.
13. Matthay, MA, Brower, RG, Carson, S, et al., for the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 184 (2011), 561–568.
14. Zeiher, BG, Artigas, A, Vincent, JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 32 (2004), 1695–1702.
15. Calfee, CS, Delucchi, K, Parsons, PE, Thompson, BT, Ware, LB, Matthay, MA, for the NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2 (2014), 611–620.
16. Brenner, JS, Greineder, C, Shuvaev, V, Muzykantov, V, Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin Drug Deliv 12 (2015), 239–261.
17. Famous, KR, Delucchi, K, Ware, LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195 (2017), 331–338.
18. Beitler, JR, Goligher, EC, Schmidt, M, et al. Personalized medicine for ARDS: the 2035 research agenda. Intensive Care Med 42 (2016), 756–767.
19. Prescott, HC, Calfee, CS, Thompson, BT, Angus, DC, Liu, VX, Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 194 (2016), 147–155.
20. Ranieri, VM, Suter, PM, Tortorella, C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 282 (1999), 54–61.
21. Parsons, PE, Eisner, MD, Thompson, BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 33 (2005), 1–6.
22. Meduri, GU, Headley, S, Kohler, G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107 (1995), 1062–1073.
23. Meduri, GU, Kohler, G, Headley, S, Tolley, E, Stentz, F, Postlethwaite, A, Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108 (1995), 1303–1314.
24. Katzenstein, AL, Bloor, CM, Leibow, AA, Diffuse alveolar damage—the role of oxygen, shock, and related factors. A review. Am J Pathol 85 (1976), 209–228.
25. Wiener-Kronish, JP, Albertine, KH, Matthay, MA, Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin. J Clin Invest 88 (1991), 864–875.
26. Meyer, NJ, Christie, JD, Genetic heterogeneity and risk for ARDS. Semin Respir Crit Care Med 34 (2013), 459–474.
27. Meyer, NJ, Beyond single-nucleotide polymorphisms: genetics, genomics, and other ‘omic approaches to acute respiratory distress syndrome’. Clin Chest Med 35 (2014), 673–684.
28. Blondonnet, R, Constantin, JM, Sapin, V, Jabaudon, M, A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers, 2016, 2016, 3501373.
29. Ware, LB, Calfee, CS, Biomarkers of ARDS: what's new?. Intensive Care Med 42 (2016), 797–799.
30. Brown, SM, Grissom, CK, Rondina, MT, et al. Polymorphisms in key pulmonary inflammatory pathways and the development of acute respiratory distress syndrome. Exp Lung Res 41 (2015), 155–162.
31. Shortt, K, Chaudhary, S, Grigoryev, D, et al. Identification of novel single nucleotide polymorphisms associated with acute respiratory distress syndrome by Exome-Seq. PLoS One, 9, 2014, e111953.
32. Sapru, A, Liu, KD, Wiemels, J, et al. Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome. Crit Care, 20, 2016, 151.
33. Ghosh, CC, David, S, Zhang, R, et al. Gene control of tyrosine kinase TIE2 and vascular manifestations of infections. Proc Natl Acad Sci USA 113 (2016), 2472–2477.
34. Evans, CR, Karnovsky, A, Kovach, MA, Standiford, TJ, Burant, CF, Stringer, KA, Untargeted LC–MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J Proteome Res 13 (2014), 640–649.
35. Stringer, KA, Serkova, NJ, Karnovsky, A, Guire, K, Paine, R, Standiford, TJ, Metabolic consequences of sepsis-induced acute lung injury revealed by plasma 1H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol 300 (2011), L4–11.
36. Calfee, CS, Janz, DR, Bernard, GR, et al. Distinct molecular phenotypes of direct versus indirect ARDS in single-center and multicenter studies. Chest 147 (2015), 1539–1548.
37. Blondonnet, R, Constantin, JM, Sapin, V, Jabaudon, M, A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers, 2016, 2016, 20.
38. Forel, JM, Guervilly, C, Hraiech, S, et al. Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. Intensive Care Med 41 (2015), 1–11.
39. Battaglia, M, Atkinson, MA, The streetlight effect in type 1 diabetes. Diabetes 64 (2015), 1081–1090.
40. Manolio, TA, Collins, FS, Cox, NJ, et al. Finding the missing heritability of complex diseases. Nature 461 (2009), 747–753.
41. Christie, JD, Wurfel, MM, Feng, R, et al. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS One, 7, 2012, e28268.
42. Angus, DC, Linde-Zwirble, WT, Lidicker, J, Clermont, G, Carcillo, J, Pinsky, MR, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001), 1303–1310.
43. Copeland, KT, Checkoway, H, McMichael, AJ, Holbrook, RH, Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 105 (1977), 488–495.
44. Tejera, P, Meyer, NJ, Chen, F, et al. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet 49 (2012), 671–680.
45. Gibson, G, Rare and common variants: twenty arguments. Nat Rev Genet 13 (2012), 135–145.
46. Tennessen, JA, Bigham, AW, O'Connor, TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337 (2012), 64–69.
47. Posey, JE, Harel, T, Liu, P, et al. Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med 376 (2017), 21–31.
48. Djebali, S, Davis, CA, Merkel, A, et al. Landscape of transcription in human cells. Nature 489 (2012), 101–108.
49. Wang, Z, Gerstein, M, Snyder, M, RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10 (2009), 57–63.
50. Gibson, G, Powell, JE, Marigorta, UM, Expression quantitative trait locus analysis for translational medicine. Genome Med, 7, 2015, 60.
51. Palakshappa, JA, Meyer, NJ, Which patients with ARDS benefit from lung biopsy?. Chest 148 (2015), 1073–1082.
52. Kovach, MA, Stringer, KA, Bunting, R, et al. Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome. Respir Res, 16, 2015, 29.
53. Aggarwal, NR, King, LS, D'Alessio, FR, Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol 306 (2014), L709–L725.
54. Kangelaris, KN, Prakash, A, Liu, KD, et al. Increased expression of neutrophil-related genes in patients with early sepsis-induced ARDS. Am J Physiol Lung Cell Mol Physiol 308 (2015), L1102–L1113.
55. Howrylak, JA, Dolinay, T, Lucht, L, et al. Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics 37 (2009), 133–139.
56. Rogers, AJ, Matthay, MA, Applying metabolomics to uncover novel biology in ARDS. Am J Physiol Lung Cell Mol Physiol 306 (2014), L957–L961.
57. Bhargava, M, Becker, TL, Viken, KJ, et al. Proteomic profiles in acute respiratory distress syndrome differentiates survivors from non-survivors. PLoS One, 9, 2014, e109713.
58. Chen, X, Shan, Q, Jiang, L, Zhu, B, Xi, X, Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. Biochem Biophys Res Commun 441 (2013), 1–6.
59. Gerszten, RE, Accurso, F, Bernard, GR, et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 295 (2008), 16–22.
60. Bos, LDJ, Weda, H, Wang, Y, et al. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome. Eur Respir J 44 (2014), 188–197.
61. Gajic, O, Dabbagh, O, Park, PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med Medicine 183 (2011), 462–470.
62. Trillo-Alvarez, C, Cartin-Ceba, R, Kor, DJ, et al. Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J 37 (2011), 604–609.
63. Dickson, RP, Singer, BH, Newstead, MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol, 1, 2016, 16113.
64. Bernard, GR, Artigas, A, Brigham, KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 (1994), 818–824.
65. Schmidt, EP, Li, G, Li, L, et al. The circulating glycosaminoglycan signature of respiratory failure in critically ill adults. J Biol Chem 289 (2014), 8194–8202.
66. Mrozek, S, Jabaudon, M, Jaber, S, et al. Elevated plasma levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: a prospective multicenter study. Chest 150 (2016), 998–1007.
67. Calfee, CS, Eisner, MD, Ware, LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 35 (2007), 2243–2250.
68. Constantin, JM, Grasso, S, Chanques, G, et al. Lung morphology predicts response to recruitment maneuver in patients with acute respiratory distress syndrome. Crit Care Med 38 (2010), 1108–1117.
69. Haldar, P, Pavord, ID, Shaw, DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178 (2008), 218–224.
70. Moore, WC, Meyers, DA, Wenzel, SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 181 (2010), 315–323.
71. Wong, HR, Cvijanovich, N, Lin, R, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med, 7, 2009, 34.
72. Wong, HR, Cvijanovich, NZ, Anas, N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med 191 (2015), 309–315.
73. Quackenbush, J, Computational analysis of microarray data. Nat Rev Genet 2 (2001), 418–427.
74. Charrad, M, Ghazzali, N, Boiteau, V, Niknafs, A, NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw, 61, 2014, 36.
75. Churpek, MM, Yuen, TC, Winslow, C, Meltzer, DO, Kattan, MW, Edelson, DP, Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med 44 (2016), 368–374.
76. Wong, HR, Lindsell, CJ, Pettila, V, et al. A multi-biomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 42 (2014), 781–789.
77. Brown, LM, Calfee, CS, Matthay, MA, Brower, RG, Thompson, BT, Checkley, W, A simple classification model for hospital mortality in patients with acute lung injury managed with lung protective ventilation. Crit Care Med 39 (2011), 2645–2651.
78. Wenzel, SE, Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18 (2012), 716–725.
79. Howard, R, Rattray, M, Prosperi, M, Custovic, A, Distinguishing asthma phenotypes using machine learning approaches. Curr Allergy Asthma Rep, 15, 2015, 38.
80. Reilly, JP, Bellamy, S, Shashaty, MGS, et al. Heterogeneous phenotypes of the acute respiratory distress syndrome after major trauma. Ann Am Thorac Soc 11 (2014), 728–736.
81. Agrawal, A, Matthay, MA, Kangelaris, KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 187 (2013), 736–742.
82. Calfee, CS, Gallagher, D, Abbott, J, Thompson, BT, Matthay, MA, Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 40 (2012), 1731–1737.
83. Fremont, RD, Koyama, T, Calfee, CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 68 (2010), 1121–1127.
84. Meyer, NJ, Li, M, Feng, R, et al. ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med 183 (2011), 1344–1353.
85. Westra, HJ, Peters, MJ, Esko, T, et al. Systematic identification of trans-eQTLs as putative drivers of known disease associations. Nat Genet 45 (2013), 1238–1243.
86. Imai, K, Keele, L, Tingley, D, A general approach to causal mediation analysis. Psychol Methods 15 (2010), 309–334.
87. Wei, Y, Wang, Z, Su, L, et al. Platelet count mediates the contribution of a genetic variant in LRRC 16A to ARDS risk. Chest 147 (2015), 607–617.
88. Wei, Y, Tejera, P, Wang, Z, et al. A missense genetic variant in LRRC16A/CAMIL1 improves ARDS survival by attenuating platelet count decline. Am J Respir Crit Care Med, 2016, 10.1164/rccm.201605-0946OC published online Oct 21.
89. Cohen, J, Pertsemlidis, A, Kotowski, IK, Graham, R, Garcia, CK, Hobbs, HH, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37 (2005), 161–165.
90. Cohen, JC, Emerging LDL therapies: using human genetics to discover new therapeutic targets for plasma lipids. J Clin Lipidol 7:suppl 3 (2013), S1–S5.
91. Huh, D, Leslie, DC, Matthews, BD, et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med, 4, 2012, 159ra147.
92. Cypel, M, Yeung, JC, Liu, M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 364 (2011), 1431–1440.
93. Chaney, J, Suzuki, Y, Cantu, E, van Berkel, V, Lung donor selection criteria. J Thorac Dis 6 (2014), 1032–1038.
94. McAuley, DF, Curley, GF, Hamid, UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol 306 (2014), L809–L815.
95. Lee, JW, Krasnodembskaya, A, McKenna, DH, Song, Y, Abbott, J, Matthay, MA, Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 187 (2013), 751–760.
96. Gores, KM, Delsing, AS, Kraus, SJ, et al. Plasma angiopoietin-2 concentrations are related to impaired lung function, and organ failure in a clinical cohort receiving high dose interleukin-2 therapy. Shock 42 (2014), 115–120.
97. Jinek, M, Chylinski, K, Fonfara, I, Hauer, M, Doudna, JA, Charpentier, E, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
98. Cockrell, AS, Yount, BL, Scobey, T, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol, 2, 2016, 16226.
99. Flaherty, KT, Robert, C, Hersey, P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367 (2012), 107–114.
100. Kris, MG, Johnson, BE, Berry, LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
101. Ortega, HG, Liu, MC, Pavord, ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
102. Freidlin, B, Korn, EL, Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 11 (2014), 81–90.
103. Mehta, C, Schafer, H, Daniel, H, Irle, S, Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Stat Med 33 (2014), 4515–4531.
104. Geiss, GK, Bumgarner, RE, Birditt, B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26 (2008), 317–325.
105. Cuenca, AG, Gentile, LF, Lopez, MC, et al. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med 41 (2013), 1175–1185.
106. Calfee, CS, Ware, LB, Eisner, MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 63 (2008), 1083–1089.
107. Matthay, MA, McAuley, DF, Ware, LB, Clinical trials in ARDS: challenges and opportunities. Lancet Respir Med 5 (2017), 524–534.